Medtronic plc (MDT) stock
MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 17/303% above fair value
$102.86+1.87 (+1.85%)
Close on Nov 13, 2026Market cap $131.57BP/E 25.3Yield 2.76%
Medtronic r&d expenses
Research and development expenses are spending on new products and technology.
Medtronic's R&D Expenses for the twelve months ending Jul 31, 2026 was $2.92B, up 4.9% year over year. For fiscal 2026 it was $2.87B, up 5.2% from the year before. Over ten years it grew 2.6% a year on average. The highest annual figure on record is $2.87B in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 24, 2026 | $2.87B | +5.2% |
| FY2025 | Apr 25, 2025 | $2.73B | -0.1% |
| FY2024 | Apr 26, 2024 | $2.74B | +1.4% |
| FY2023 | Apr 28, 2023 | $2.70B | -1.8% |
| FY2022 | Apr 29, 2022 | $2.75B | +10.1% |
| FY2021 | Apr 30, 2021 | $2.49B | +6.9% |
| FY2020 | Apr 24, 2020 | $2.33B | +0.0% |
| FY2019 | Apr 26, 2019 | $2.33B | +3.3% |
| FY2018 | Apr 27, 2018 | $2.26B | +2.9% |
| FY2017 | Apr 28, 2017 | $2.19B | -1.4% |
| FY2016 | Apr 29, 2016 | $2.22B | +35.6% |
| FY2015 | Apr 24, 2015 | $1.64B | +11.0% |
| FY2014 | Apr 25, 2014 | $1.48B | -5.1% |
| FY2013 | Apr 26, 2013 | $1.56B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $771.00M | +6.2% |
| Q4 FY2026CQ1 2026 | Apr 24, 2026 | $671.00M | -1.9% |
| Q3 FY2026CQ4 2025 | Jan 23, 2026 | $722.00M | +7.0% |
| Q2 FY2026CQ3 2025 | Oct 24, 2025 | $754.00M | +8.2% |
| Q1 FY2026CQ2 2025 | Jul 25, 2025 | $726.00M | +7.4% |
| Q4 FY2025CQ1 2025 | Apr 25, 2025 | $684.00M | +1.3% |
| Q3 FY2025CQ4 2024 | Jan 24, 2025 | $675.00M | -2.9% |
| Q2 FY2025CQ3 2024 | Oct 25, 2024 | $697.00M | -0.1% |
| Q1 FY2025CQ2 2024 | Jul 26, 2024 | $676.00M | +1.2% |
| Q4 FY2024CQ1 2024 | Apr 26, 2024 | $675.00M | +5.3% |
| Q3 FY2024CQ4 2023 | Jan 26, 2024 | $695.00M | +1.0% |
| Q2 FY2024CQ3 2023 | Oct 27, 2023 | $698.00M | +3.3% |
| Q1 FY2024CQ2 2023 | Jul 28, 2023 | $668.00M | -3.5% |
| Q4 FY2023CQ1 2023 | Apr 28, 2023 | $641.00M | -1.7% |
| Q3 FY2023CQ4 2022 | Jan 27, 2023 | $688.00M | +3.0% |
| Q2 FY2023CQ3 2022 | Oct 28, 2022 | $676.00M | 0.0% |
| Q1 FY2023CQ2 2022 | Jul 29, 2022 | $692.00M | -7.7% |
| Q4 FY2022CQ1 2022 | Apr 29, 2022 | $652.00M | +3.2% |
| Q3 FY2022CQ4 2021 | Jan 28, 2022 | $668.00M | +11.1% |
| Q2 FY2022CQ3 2021 | Oct 29, 2021 | $676.00M | +5.8% |
| Q1 FY2022CQ2 2021 | Jul 30, 2021 | $750.00M | +20.8% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $632.00M | +11.3% |
| Q3 FY2021CQ4 2020 | Jan 29, 2021 | $601.00M | +4.9% |
| Q2 FY2021CQ3 2020 | Oct 30, 2020 | $639.00M | +6.0% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $621.00M | +5.8% |
| Q4 FY2020CQ1 2020 | Apr 24, 2020 | $568.00M | -4.4% |
| Q3 FY2020CQ4 2019 | Jan 24, 2020 | $573.00M | +2.1% |
| Q2 FY2020CQ3 2019 | Oct 25, 2019 | $603.00M | +2.2% |
| Q1 FY2020CQ2 2019 | Jul 26, 2019 | $587.00M | +0.3% |
| Q4 FY2019CQ1 2019 | Apr 26, 2019 | $594.00M | +0.3% |
| Q3 FY2019CQ4 2018 | Jan 25, 2019 | $561.00M | +0.4% |
| Q2 FY2019CQ3 2018 | Oct 26, 2018 | $590.00M | +6.1% |
| Q1 FY2019CQ2 2018 | Jul 27, 2018 | $585.00M | +6.6% |
| Q4 FY2018CQ1 2018 | Apr 27, 2018 | $592.00M | +7.1% |
| Q3 FY2018CQ4 2017 | Jan 26, 2018 | $559.00M | +5.5% |
| Q2 FY2018CQ3 2017 | Oct 27, 2017 | $556.00M | +0.4% |
| Q1 FY2018CQ2 2017 | Jul 28, 2017 | $549.00M | – |
| Q4 FY2017CQ1 2017 | Apr 28, 2017 | $553.00M | – |
| Q3 FY2017CQ4 2016 | Jan 27, 2017 | $530.00M | – |
| Q2 FY2017CQ3 2016 | Oct 28, 2016 | $554.00M | – |
See a number that looks wrong?